| UHC Commercial Medical & Drug | Electrical and Ultrasonic Bone Growth Stimulators – Commercial and Individual Exchange Medical Policy | 2026-02-01 |
| UHC Commercial Medical & Drug | Infliximab (Avsola®, Inflectra®, Remicade®, & Renflexis®) – Commercial Medical Benefit Drug Policy | 2026-02-01 |
| UHC Commercial Medical & Drug | Intravenous Iron Replacement Therapy (Feraheme®, Injectafer®, & Monoferric®) – Commercial Medical Benefit Drug Policy | 2026-02-01 |
| UHC Commercial Medical & Drug | Kisunla™ (Donanemab-Azbt) – Commercial Medical Benefit Drug Policy | 2026-02-01 |
| UHC Commercial Medical & Drug | Manipulation Under Anesthesia – Commercial and Individual Exchange Medical Policy | 2026-02-01 |
| UHC Commercial Medical & Drug | Minimally Invasive Procedures for the Treatment of Upper Gastrointestinal Diseases – Commercial and Individual Exchange Medical Policy | 2026-02-01 |
| UHC Commercial Medical & Drug | Minimally Invasive Spine Surgery Procedures – Commercial and Individual Exchange Medical Policy | 2026-02-01 |
| UHC Commercial Medical & Drug | Tepezza® (Teprotumumab-Trbw) – Commercial Medical Benefit Drug Policy | 2026-02-01 |
| UHC Commercial Medical & Drug | Tezspire® (Tezepelumab-Ekko) – Commercial Medical Benefit Drug Policy | 2026-02-01 |
| UHC Commercial Medical & Drug | Total Artificial Disc Replacement for the Spine – Commercial and Individual Exchange Medical Policy | 2026-02-01 |